Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin

Retina

Volumn 22, Issue 6, 2002, Pages 691-697

  Houle, Jean Marie ^a   Andrew Strong, H ^a  

^a QLT Inc   (United States)

Author keywords

Photodynamic therapy; Photosensitivity; Verteporfin therapy; Visudyne

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIGHT EXPOSURE; MALE; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SKIN TOXICITY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

EID: 0036903198     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200212000-00002     Document Type: Article

References (10)

1. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
2. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-Year results of a randomized clinical trial - VIP Report No. 1. Ophthalmology 2001;108:841-852.
3. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 2-Year results of a randomized clinical trial - VIP Report No. 3. Ophthalmology 2002 (submitted for publication).
4. Saperstein DA, Rosenfeld PJ, Bressler NM, et al, Vertparfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: One-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109:1499-1505.
5. Bellnier DA, Dougherty TJ. A preliminary pharmacokinetic study of intravenous Photofrin® in patients. J Clin Laser Med Surg 1996;14:311-314.
6. Wooten RS, Smith KC, Ahlquist DA, et al. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg Med 1988;8:294-300.
7. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994;59:328-335.
8. Houle J-M, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002;42:547-557.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
10. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Verteporfin in Photodynamic Therapy (VIP) Study Group. Guidelines for using verteporfin (Visudyne®) in -photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.